V. Trillet-Lenoir

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

V. Trillet-Lenoir, J. Green, C. Manegold et al. · European Journal of Cancer · 1993 · 545 citations

Medicine, Immunology, Oncology +15

Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy

Jean‐Marc Nabholtz, H.-J. Senn, W.R. Bezwoda et al. · Journal of Clinical Oncology · 1999 · 506 citations

Medicine, Oncology, Pharmacology +12

Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure and Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis: Morbidity and Mortality Analysis of 216 Consecutive Procedures

Olivier Gléhen, D. Osinsky, Eddy Cotte et al. · Annals of Surgical Oncology · 2003 · 342 citations

Medicine, Oncology, Surgery +12

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

Bruno Coudert, Rémy Largillier, Laurent Arnould et al. · Journal of Clinical Oncology · 2007 · 133 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9